Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
48
RDY Quote, Financials, Valuation and Earnings
Last price:
$14.13
Seasonality move
:
4.79%
Day range:
$14.45 - $14.55
52-week range:
$12.26 - $16.17
Dividend yield:
0.66%
P/E ratio:
18.13x
P/S ratio:
2.97x
P/B ratio:
2.84x
Volume:
3.1M
Avg. volume:
2M
1-year change:
14.4%
Market cap:
$11.8B
Revenue:
$3.9B
EPS (TTM):
$0.78
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$929.2M | $0.19 | -4.23% | 3.83% | $14.32 |
|
HDB
HDFC Bank Ltd.
|
$5B | $0.39 | -62.65% | -8.15% | $42.95 |
|
INFY
Infosys Ltd.
|
$5B | $0.20 | 5.1% | 5% | $18.40 |
|
NVO
Novo Nordisk A/S
|
$12.2B | $0.94 | 5.66% | 10.93% | $47.48 |
|
YI
111, Inc.
|
$514.9M | -- | -4.26% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$122.7M | -$0.42 | 10.78% | -4.05% | $39.10 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$14.13 | $14.32 | $11.8B | 18.13x | $0.09 | 0.66% | 2.97x |
|
HDB
HDFC Bank Ltd.
|
$28.23 | $42.95 | $144.8B | 13.88x | $0.38 | 1.33% | 2.21x |
|
INFY
Infosys Ltd.
|
$13.27 | $18.40 | $53.7B | 17.13x | $0.26 | 3.92% | 2.77x |
|
NVO
Novo Nordisk A/S
|
$37.96 | $47.48 | $168.7B | 10.95x | $0.58 | 4.55% | 3.61x |
|
YI
111, Inc.
|
$6.58 | -- | $57M | -- | $0.00 | 0% | 0.03x |
|
ZLAB
Zai Lab Ltd.
|
$18.37 | $39.10 | $2.1B | -- | $0.00 | 0% | 4.36x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
15.39% | -0.302 | 6.43% | 1.19x |
|
HDB
HDFC Bank Ltd.
|
52.16% | -0.516 | 36.09% | 4.85x |
|
INFY
Infosys Ltd.
|
9.58% | 1.122 | 1.36% | 1.53x |
|
NVO
Novo Nordisk A/S
|
40.29% | 2.221 | 9.11% | 0.46x |
|
YI
111, Inc.
|
-42.73% | -0.183 | 17.3% | 0.41x |
|
ZLAB
Zai Lab Ltd.
|
23.86% | 0.191 | 11.48% | 2.18x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RDY
Dr. Reddy's Laboratories Ltd.
|
$525.4M | $154.2M | 13.68% | 15.8% | 15.74% | $32.9M |
|
HDB
HDFC Bank Ltd.
|
-- | $3B | 6.54% | 13.98% | 57.34% | -- |
|
INFY
Infosys Ltd.
|
$1.4B | $958.1M | 27.44% | 29.93% | 18.77% | $923.9M |
|
NVO
Novo Nordisk A/S
|
$10B | $5B | 37.26% | 62.44% | 40.32% | -$5.4B |
|
YI
111, Inc.
|
$24.9M | -$302.8K | -15.3% | -26.11% | -0.07% | $5.3M |
|
ZLAB
Zai Lab Ltd.
|
$65.6M | -$69.7M | -17.96% | -22.45% | -54.4% | -$19.1M |
Dr. Reddy's Laboratories Ltd. vs. Competitors
-
Which has Higher Returns RDY or HDB?
HDFC Bank Ltd. has a net margin of 13.63% compared to Dr. Reddy's Laboratories Ltd.'s net margin of 16.3%. Dr. Reddy's Laboratories Ltd.'s return on equity of 15.8% beat HDFC Bank Ltd.'s return on equity of 13.98%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.53.64% $0.16 $4.9B HDBHDFC Bank Ltd.-- $0.43 $133.8B -
What do Analysts Say About RDY or HDB?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.32, signalling upside risk potential of 1.37%. On the other hand HDFC Bank Ltd. has an analysts' consensus of $42.95 which suggests that it could grow by 52.14%. Given that HDFC Bank Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe HDFC Bank Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 HDBHDFC Bank Ltd.3 0 0 -
Is RDY or HDB More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.337, which suggesting that the stock is 66.33% less volatile than S&P 500. In comparison HDFC Bank Ltd. has a beta of 0.559, suggesting its less volatile than the S&P 500 by 44.115%.
-
Which is a Better Dividend Stock RDY or HDB?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.66%. HDFC Bank Ltd. offers a yield of 1.33% to investors and pays a quarterly dividend of $0.38 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. HDFC Bank Ltd. pays out 19.48% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or HDB?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $979.5M, which are smaller than HDFC Bank Ltd. quarterly revenues of $14.2B. Dr. Reddy's Laboratories Ltd.'s net income of $133.5M is lower than HDFC Bank Ltd.'s net income of $2.3B. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 18.13x while HDFC Bank Ltd.'s PE ratio is 13.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.97x versus 2.21x for HDFC Bank Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.97x 18.13x $979.5M $133.5M HDBHDFC Bank Ltd.2.21x 13.88x $14.2B $2.3B
-
Which has Higher Returns RDY or INFY?
Infosys Ltd. has a net margin of 13.63% compared to Dr. Reddy's Laboratories Ltd.'s net margin of 14.66%. Dr. Reddy's Laboratories Ltd.'s return on equity of 15.8% beat Infosys Ltd.'s return on equity of 29.93%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.53.64% $0.16 $4.9B INFYInfosys Ltd.28.2% $0.18 $10.3B -
What do Analysts Say About RDY or INFY?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.32, signalling upside risk potential of 1.37%. On the other hand Infosys Ltd. has an analysts' consensus of $18.40 which suggests that it could grow by 38.63%. Given that Infosys Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Infosys Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 INFYInfosys Ltd.2 8 1 -
Is RDY or INFY More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.337, which suggesting that the stock is 66.33% less volatile than S&P 500. In comparison Infosys Ltd. has a beta of 1.019, suggesting its more volatile than the S&P 500 by 1.85%.
-
Which is a Better Dividend Stock RDY or INFY?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.66%. Infosys Ltd. offers a yield of 3.92% to investors and pays a quarterly dividend of $0.26 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Infosys Ltd. pays out 56.51% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or INFY?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $979.5M, which are smaller than Infosys Ltd. quarterly revenues of $5.1B. Dr. Reddy's Laboratories Ltd.'s net income of $133.5M is lower than Infosys Ltd.'s net income of $748.2M. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 18.13x while Infosys Ltd.'s PE ratio is 17.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.97x versus 2.77x for Infosys Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.97x 18.13x $979.5M $133.5M INFYInfosys Ltd.2.77x 17.13x $5.1B $748.2M
-
Which has Higher Returns RDY or NVO?
Novo Nordisk A/S has a net margin of 13.63% compared to Dr. Reddy's Laboratories Ltd.'s net margin of 33.98%. Dr. Reddy's Laboratories Ltd.'s return on equity of 15.8% beat Novo Nordisk A/S's return on equity of 62.44%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.53.64% $0.16 $4.9B NVONovo Nordisk A/S80.86% $0.94 $51.1B -
What do Analysts Say About RDY or NVO?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.32, signalling upside risk potential of 1.37%. On the other hand Novo Nordisk A/S has an analysts' consensus of $47.48 which suggests that it could grow by 25.08%. Given that Novo Nordisk A/S has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Novo Nordisk A/S is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 NVONovo Nordisk A/S4 8 0 -
Is RDY or NVO More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.337, which suggesting that the stock is 66.33% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.733, suggesting its less volatile than the S&P 500 by 26.748%.
-
Which is a Better Dividend Stock RDY or NVO?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.66%. Novo Nordisk A/S offers a yield of 4.55% to investors and pays a quarterly dividend of $0.58 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Novo Nordisk A/S pays out 38.07% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or NVO?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $979.5M, which are smaller than Novo Nordisk A/S quarterly revenues of $12.3B. Dr. Reddy's Laboratories Ltd.'s net income of $133.5M is lower than Novo Nordisk A/S's net income of $4.2B. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 18.13x while Novo Nordisk A/S's PE ratio is 10.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.97x versus 3.61x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.97x 18.13x $979.5M $133.5M NVONovo Nordisk A/S3.61x 10.95x $12.3B $4.2B
-
Which has Higher Returns RDY or YI?
111, Inc. has a net margin of 13.63% compared to Dr. Reddy's Laboratories Ltd.'s net margin of -0.5%. Dr. Reddy's Laboratories Ltd.'s return on equity of 15.8% beat 111, Inc.'s return on equity of -26.11%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.53.64% $0.16 $4.9B YI111, Inc.5.93% -$0.21 $59.5M -
What do Analysts Say About RDY or YI?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.32, signalling upside risk potential of 1.37%. On the other hand 111, Inc. has an analysts' consensus of -- which suggests that it could grow by 812.48%. Given that 111, Inc. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe 111, Inc. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 YI111, Inc.0 0 0 -
Is RDY or YI More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.337, which suggesting that the stock is 66.33% less volatile than S&P 500. In comparison 111, Inc. has a beta of 0.546, suggesting its less volatile than the S&P 500 by 45.375%.
-
Which is a Better Dividend Stock RDY or YI?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.66%. 111, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. 111, Inc. pays out -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or YI?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $979.5M, which are larger than 111, Inc. quarterly revenues of $419.3M. Dr. Reddy's Laboratories Ltd.'s net income of $133.5M is higher than 111, Inc.'s net income of -$2.1M. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 18.13x while 111, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.97x versus 0.03x for 111, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.97x 18.13x $979.5M $133.5M YI111, Inc.0.03x -- $419.3M -$2.1M
-
Which has Higher Returns RDY or ZLAB?
Zai Lab Ltd. has a net margin of 13.63% compared to Dr. Reddy's Laboratories Ltd.'s net margin of -39.51%. Dr. Reddy's Laboratories Ltd.'s return on equity of 15.8% beat Zai Lab Ltd.'s return on equity of -22.45%.
Company Gross Margin Earnings Per Share Invested Capital RDYDr. Reddy's Laboratories Ltd.53.64% $0.16 $4.9B ZLABZai Lab Ltd.51.15% -$0.46 $939.8M -
What do Analysts Say About RDY or ZLAB?
Dr. Reddy's Laboratories Ltd. has a consensus price target of $14.32, signalling upside risk potential of 1.37%. On the other hand Zai Lab Ltd. has an analysts' consensus of $39.10 which suggests that it could grow by 112.86%. Given that Zai Lab Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Zai Lab Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..
Company Buy Ratings Hold Ratings Sell Ratings RDYDr. Reddy's Laboratories Ltd.2 2 1 ZLABZai Lab Ltd.8 1 0 -
Is RDY or ZLAB More Risky?
Dr. Reddy's Laboratories Ltd. has a beta of 0.337, which suggesting that the stock is 66.33% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.854, suggesting its less volatile than the S&P 500 by 14.611%.
-
Which is a Better Dividend Stock RDY or ZLAB?
Dr. Reddy's Laboratories Ltd. has a quarterly dividend of $0.09 per share corresponding to a yield of 0.66%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr. Reddy's Laboratories Ltd. pays 8.91% of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RDY or ZLAB?
Dr. Reddy's Laboratories Ltd. quarterly revenues are $979.5M, which are larger than Zai Lab Ltd. quarterly revenues of $128.2M. Dr. Reddy's Laboratories Ltd.'s net income of $133.5M is higher than Zai Lab Ltd.'s net income of -$50.6M. Notably, Dr. Reddy's Laboratories Ltd.'s price-to-earnings ratio is 18.13x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr. Reddy's Laboratories Ltd. is 2.97x versus 4.36x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RDYDr. Reddy's Laboratories Ltd.2.97x 18.13x $979.5M $133.5M ZLABZai Lab Ltd.4.36x -- $128.2M -$50.6M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
92
APEI alert for Mar 13
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Buy
52
PZZA alert for Mar 13
Papa John's International, Inc. [PZZA] is down 5.25% over the past day.
Buy
53
NBIS alert for Mar 13
Nebius Group NV [NBIS] is up 0.87% over the past day.
